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ompared with balloon angioplasty, implantation of
coronary stents has significantly decreased resteno-
sis,1–5 but in-stent restenosis caused by neointimal
hyperplasia can occur in 20–30% of cases following bare
metal stent implantation6–10 and clinical in-stent restenosis
or ischemia-driven revascularization for significant resteno-
sis (≥50%) occurs in 10–15% following implantation of
bare metal stents. This process usually occurs within 1 year
of the index procedure and is believed to have a benign
presentation with recurrent angina and/or evidence of
ischemia on a stress test. However, there is scant data of an
acute event such as myocardial infarction (MI) presenting
as clinical in-stent restenosis. We sought to determine the
incidence and type of MI, as well as clinical and angiogra-
phic characteristics of patients presenting with clinical in-
stent restenosis (namely, any recurrent ischemia occurring
in the stented segment) from our single center experience.
Methods
Study Patients
Of 2,462 consecutive patients who underwent percuta-
neous coronary interventions (PCI) with bare metal stents
between June 2001 and December 2002, 212 (8.6%) were
found to have clinical in-stent restenosis, which was defined
as angiographic stenosis >50% within 5mm of the stented
segment for patients presenting for an angiogram for clini-
cal evidence of ischemia (viz. angina or positive stress test).
Patients presenting within 30 days of index procedure, with
recurrent in-stent restenosis or restenosis following balloon
angioplasty only, and patients presenting with MI clearly
attributable to non-restenotic lesion or vessel were excluded.
The antiplatelet regimen after the initial stent deployment
was aspirin 325mg daily indefinitely, and clopidogrel 75mg
daily for 4 weeks following a loading dose of 300mg on the
day of the procedure. The average follow-up period was
205±23 days (median 124 days). Based on the presenting
symptoms and findings, the patients were divided into 3
groups: ST elevation MI (STEMI), non-ST elevation MI
(NSTEMI), and non-MI groups. Patients with elevation of
creatinine kinase (CK) 2-fold more than the normal refer-
ence with elevated MB fraction were considered to have a
MI. Patients with STEMI were to have >1mm ST-segment
elevation in ≥2 contiguous leads. The NSTEMI group had
elevated cardiac enzymes as above, without ST-segment
elevation on the ECG. Renal failure was defined as baseline
serum creatinine >2.0mg/dl. The angiographic pattern of in-
stent restenosis was analyzed as classified by Mehran et al.11
Clinical and angiographic characteristics were compared
among the 3 groups. Informed consent was given by each
patient and the study protocol was approval by the institu-
tional review board.
Statistical Analysis
Quantitative data are presented as mean value±1 SD or
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Background In-stent restenosis is considered to be a gradual and progressive condition and there is scant data
on myocardial infarction (MI) as a clinical presentation.
Methods and Results Of 2,462 consecutive patients who underwent percutaneous coronary intervention
between June 2001 and December 2002, clinical in-stent restenosis occurred in 212 (8.6%), who were classified
into 3 groups: ST elevation MI (STEMI), non-ST elevation MI (NSTEMI) and non-MI. Of the 212 patients
presenting with clinical in-stent restenosis, 22 (10.4%) had MI (creatine kinase (CK) ≥2×baseline with elevated
CKMB). The remaining 190 (89.6%) patients had stable angina or evidence of ischemia by stress test without
elevation of cardiac enzymes. Median interval between previous intervention and presentation for clinical in-
stent restenosis was shorter for patients with MI than for non-MI patients (STEMI, 90 days; NSTEMI, 79 days;
non-MI, 125 days; p=0.07). Diffuse in-stent restenosis was more frequent in MI patients than in non-MI patients
(72.7% vs 56.3%; p<0.005). Renal failure was more prevalent in patients with MI than in those without MI
(31.8% vs 6.3%, p=0.001). Compared with the non-MI group, patients with MI were more likely to have acute
coronary syndromes at the time of index procedure (81.8% vs 56.8%, p=0.02).
Conclusion Clinical in-stent restenosis can frequently present as MI and such patients are more likely to have
an aggressive angiographic pattern of restenosis. Renal failure and acute coronary syndromes at the initial proce-
dure are associated with MI. (Circ J 2006; 70: 1026–1029)
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median (range), and qualitative data as frequencies. Contin-
uous variables were compared using analysis of variance or
Kruskal-Wallis analysis. Bonferroni-Dunn method was used
for post-hoc analyses. Categorical variables were examined
by chi-square test or Fisher’s exact test. All probability
values are two-tailed and p-value <0.05 was considered sta-
tistically significant. Statistical analysis was performed with
StatView 5.0 (Abacus Concepts Inc, Calabasus, CA, USA).
Results
Clinical and Angiographic Characteristics
Of the 212 patients with clinical in-stent restenosis, 22
(10.4%) presented with MI (Table1) and of these, 10 (4.7%)
had STEMI and 12 (5.7%) had NSTEMI. The remaining
190 (89.6%) patients had angina or evidence of ischemia
by stress test without elevation of cardiac enzymes. Of
these patients, 22 patients (11.6%) also had isolated eleva-
tion of troponin I ≥2ng/ml without elevation of CK or the
MB fraction or ECG changes, but were not classified as
having MI in our study. Renal failure was more prevalent in
patients with MI than in those without MI (31.8% vs 6.3%,
p=0.001). Compared with the non-MI group, patients with
MI were more likely to have acute coronary syndromes at
the time of index procedure (81.8% vs 56.8%, p=0.02).
Median interval between previous intervention and presen-
tation for clinical in-stent restenosis was 90 days in the
STEMI, 79 days in NSTEMI and 125 days in non-MI
groups (p=0.07). Of the 22 patients with MI, premature
cessation of clopidogrel within 4 weeks was noted in 2 pa-
tients (9.1%). At the time of MI, 10 patients (45.5%) were
on single antiplatelet therapy (either with aspirin or with
clopidogrel) and of these the average interval between the
index procedure and presentation as MI was 253±344 days
(median 137 days).
The mean stent diameter was similar among the 3 groups.
The mean stent length was 24.1mm overall, without statisti-
cal significance among the groups (STEMI, 28.7±17.3mm;
NSTEMI, 20.8±13.0mm and non-MI, 20.9±10.3mm; p<
0.23). Total occlusion of the target lesion occurred more
frequently in patients who presented with STEMI (50%)
than in those with NSTEMI (25%) or without MI (7.4%).
Angiographic Pattern of In-Stent Restenosis
The angiographic pattern of in-stent restenosis was sig-
nificantly different between the MI group in total and the
non-MI group (Table 2). Patients with MI had a more
aggressive type of in-stent restenosis. Total occlusion with
Thrombolysis in Myocardial Infarction flow grade 0 ap-
peared to be more frequent in patients with STEMI whereas
focal restenosis appeared more frequently in patients with
NSTEMI. Of the 22 patients with MI, 11 (50%) had an
angiographically visible thrombus. An angiogram from a
patient with STEMI is shown in Fig1, with the pattern sug-
gesting profuse in-stent restenosis rather than late stent
thrombosis as a cause of MI in this case.
Table 1 Clinical Characteristics
STEMI NSTEMI Non-MI p value
Age (years) 64.4±9     67.4±14   64.6±12   0.70
Male, n (%)   8 (80)  12 (100) 124 (65) 0.03
Diabetes, n (%)   2 (20)    6 (50)    69 (36) 0.35
Hypertension, n (%)   8 (80)  12 (100) 164 (86) 0.32
Hyperlipidemia, n (%) 10 (100) 10 (83)  183 (96) 0.08
Smoking, n (%)   9 (90)  10 (83)  131 (68) 0.22
Renal failure, n (%)   2 (20)    5 (42)    12 (6)      0.001*
Vessels treated, n (%)
    LAD   5 (50)    2 (17)    69 (36)
    LCX   1 (10)    5 (41)    41 (21)
0.46
    RCA   3 (30)    3 (25)    58 (30)
    SVG   1 (10)    2 (17)     14 (7.4)
Presentation at the time of index PCI, n (%)   0.02*
    Stable effort angina   2 (20)    2 (17)    82 (43)
    Acute coronary syndromes   8 (80)  10 (83)  108 (57)
Stent length (mm) 28.7±17.3 20.8±13.0 20.9±10.3 0.23
Stent diameter (mm) 3.1±0.3 3.2±0.6 3.1±0.5 0.68
Median interval to event (range) (days) 90 (31–1,296) 79 (40–1,450) 125 (31–1,433)  0.07
Diameter stenosis (%) 98.9±3.1  91.1±9.5      86.0±12.9** <0.005 
Ejection fraction (%) 32.5±13.9 43.1±12.5     49.5±12.6** <0.005 
*Comparison was made between combined MI and non-MI groups, **p<0.005 vs STEMI.
STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; MI, myocardial infarction; LAD, left 
anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; SVG, saphenous vein graft; 
PCI, percutaneous coronary intervention.
Table 2 Angiographic Patterns of In-Stent Restenosis
MI total (n=22)
Non-MI (n=190) p value*
STEMI (n=10) NSTEMI (n=12)
Focal, n (%) 1 (10.0) 5 (41.7) 83 (43.7) 0.14  
Diffuse intrastent, n (%) 1 (10.0) 0 (0)     59 (31.1) 0.009
Diffuse proliferative, n (%) 3 (30.0) 4 (33.3) 34 (17.9) 0.15  
Total occlusion, n (%) 5 (50.0) 3 (25.0) 14 (7.4)  0.005
*Comparison between combined MI and non-MI groups.
See Table 1 for abbreviations.
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Treatment
Most in-stent restenosis lesions were treated with balloon
angioplasty followed by brachytherapy. AngioJet rheolytic
thrombectomy (Possis Medical, Minneapolis, MN, USA)
was performed prior to balloon angioplasty in 1 patient in
the STEMI group because of significant thrombus burden.
There was differential use of brachytherapy, with 30%
of patients with MI treated with adjunctive brachytherapy
as opposed to 66% of patients who did not present with MI.
There were several reasons for not using brachytherapy in
all patients, namely, presence of thrombus at the lesion and
resistance of operators to use brachytherapy for acute
events, failure to cross the catheter to the lesion and non-
availability of a radiation physicist for emergency proce-
dures.
In-Hospital Mortality
In-hospital deaths occurred in 3 patients with NSTEMI,
giving an overall mortality of 1.4%. The first patient was a
64-year-old man with a history of bypass surgery and end-
stage renal artery disease on hemodialysis, who presented
with cardiogenic shock and respiratory failure 2 months
after stenting of a saphenous vein graft to the circumflex
artery. He underwent successful intervention for in-stent
restenosis in the vein graft, but died 4 days later from pneu-
monia.
Another patient was a 73-year-old man who was admitted
with NSTEMI and respiratory failure requiring intubation.
He underwent successful balloon angioplasty for in-stent
restenosis of the dominant left circumflex artery 50 days
after the initial procedure, but died 10 days later from ex-
tensive pneumonia.
The third patient was a 67-year-old male with endstage
renal disease, who developed cardiogenic shock during
hemodialysis 3 months after initial stent placement in the
dominant circumflex artery. He underwent successful repeat
intervention of the circumflex lesion. At the time of presen-
tation, he was also suffering from acute bilateral lower
extremity ischemia, for which emergency common femoral
and iliac thrombectomy was performed. The patient died
shortly after surgery from intractable cardiogenic shock.
Discussion
In our series of 212 consecutive patients who presented
with clinical in-stent restenosis, MI occurred in 10.4%
patients (4.7% with STEMI, 5.7% with NSTEMI). There
are scant data on MI as a presentation of clinical in-stent
restenosis. In their study of 234 patients who underwent
intervention for in-stent restenosis, Bossi et al reported that
3.5% of the patients had MI on presentation,12 and Walters
et al reported NSTEMI in 12% of patients and STEMI in
8% of patients who presented with clinical in-stent resteno-
sis.13 The incidence of MI in our study may have been un-
derestimated because only patients who returned to Lahey
Clinic Medical Center with recurrence of ischemia are
included in this study. In addition, the number may under-
estimate the actual incidence because of our more stringent
definition of MI. Only patients who have CK ≥2 – fold
greater than baseline with elevated MB were included. The
main reason to use such a definition was to exclude patients
who present with acute coronary syndrome with minor
enzyme elevations. We also excluded patients presenting
within 30 days of the index procedure for repeat revascu-
larization because of the possibility of stent thrombosis as a
cause of MI. In our study, 11.6% of the patients in non-MI
group had elevation of troponin I ≥2ng/ml. If these patients
are included as MI, the incidence of MI would be 20.8%,
similar to that reported by Walters et al.
Mechanisms of MI in Clinical In-Stent Restenosis
The mechanism of late MI associated with stenosis of
the stented segment is unclear. In-stent restenosis occurs be-
cause of gradual progressive smooth muscle cell prolifera-
tion resulting in neointimal hyperplasia within the stent,14,15
whereas MI is a result of rapid plaque growth with ulcera-
tion or plaque rupture and sudden compromise of the vessel
lumen. The most likely explanations for MI is late stent
thrombosis because of incomplete neointimal coverage of
the stent, early termination of antiplatelet therapy, and in-
creased thrombogenic tissue factor in the neointimal tissue
with a higher propensity of thrombosis.16 Intracoronary
angioscopy studies have shown that complete coverage of a
stent by neointimal tissue takes 3 months or longer.17,18 In
our study, the median interval between the index procedure
and presentation as clinical in-stent restenosis was 90 days
in STEMI patients, and 79 days in NSTEMI patients. These
data call for prolonged dual antiplatelet therapy even after
PCI with bare-metal stents.
The observed association of renal failure and acute coro-
nary syndromes at the time of index procedure with MI is
in line with previous reports on stent thrombosis. Iakovou
et al identified renal failure as a predictive factor of throm-
bosis after implantation of drug-eluting stents.19 In a study
of bare-metal stents by Heller et al, a discharge diagnosis of
MI was associated with an increased incidence of stent
thrombosis.20 These results support the theory that stent
thrombosis is a major cause of late MI.
According to previous reports, the incidence of late stent
thrombosis defined as stent thrombosis occurring >30 days
post procedure ranges from 0.4% to 0.8%.20–22 The inci-
dence of late MI in our study population was 0.9%, which
Fig1. Coronary angiogram in the right anterior oblique view from a
63-year-old man with ST elevation myocardial infarction. The ECG
shows ST elevation in the I and aVL leads, and the angiogram reveals
diffuse in-stent restenosis of the left circumflex stent with Throm-
bolysis in Myocardial Infarction grade I flow.
1029Clinical Presentation of In-Stent Restenosis
Circulation Journal   Vol.70, August 2006
is slightly higher than those reports. Although the primary
cause of the late MI would be late stent thrombosis, the
somewhat higher incidence of MI in the present report
suggests mechanisms other than that.
Another potential explanation for MI could be the reste-
nosis itself. Stent restenosis is associated with more aggres-
sive neointimal hyperplasia compared with restenosis
following balloon angioplasty alone, which occurs predom-
inantly because of elastic recoil. This profuse in-stent
restenosis may then be associated with diminished flow in
the vessel leading to MI (Fig 1). In contrast, restenosis
associated with balloon angioplasty has a lower incidence
of MI.13 We found that patients with STEMI were more
likely to have total occlusion (50%) and an aggressive in-
stent restenosis pattern (40% had diffuse or proliferative)
compared with the NSTEMI group (25% and 33%, respec-
tively) supporting the hypothesis that aggressive restenosis
may be associated with MI.
Study Limitations
This is a retrospective analysis from a single center. The
patient subset was limited to those who had recurrent
symptoms and did not include patients with silent resteno-
sis or ischemia. Angiographical analysis was performed
visually by 2 experienced operators and not by an indepen-
dent core laboratory with quantitative analysis. Finally,
intravascular ultrasound data were not available, which
would be useful for evaluating the cause of stent thrombo-
sis, such as underdilataion of the stent, as well as detecting
unstable plaque in the adjacent non-stented segment. How-
ever, we believe this study still provides a “real world” view
of the incidence of MI as a presentation of clinical in-stent
restenosis.
Conclusion
The present study shows that clinical in-stent restenosis
can frequently present as a MI. Patients with MI are more
likely to have renal failure and acute coronary syndromes
at the initial procedure. Angiographically, patients with MI
tend to have an aggressive pattern of restenosis and total
occlusion of the target lesion. With the advent of drug-
eluting stents, it will be interesting to see if the derease in
restenosis and possible change in the pattern of restenosis
will translate into a reduction in MI.23,24 In the meantime,
there may be a role for aggressive secondary prevention
treatments, including longer duration of antiplatelet thera-
py, to reduce the incidence of these recurrent events.25,26
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